Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 97,147

Document Document Title
WO/2014/059185A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, inde...  
WO/2014/059115A1
Provided herein are methods, assays and compositions relating to the treatment of neurological diseases and disorders, particularly by modulating expression and/or activity of Bif-1.  
WO/2014/057179A1
The invention concerns a gaseous composition containing gaseous xenon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/059306A1
The present invention relates to pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of depression and/or anxiety.  
WO/2014/057995A1
The objective of the present invention is to provide an extract from inflamed rabbit skin inoculated with vaccinia virus and formulations, etc. including the extract which have greater uniformity in quality. By using the amount of N-acet...  
WO/2014/058071A1
The present invention provides a compound that: has a lysine-specific demethylase-1-inhibiting effect; and provides utility as a drug for preventing or treating schizophrenia, Alzheimer's disease, Parkinson's disease, and Huntington chor...  
WO/2014/057266A1
The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of dise...  
WO/2014/058875A3
Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments...  
WO/2014/059346A1
Disclosed embodiments are related to pharmaceutical compositions and methods for preventing or treating conditions involving dopamine, such as Parkinson's disease, comprising administering to a mammal in need thereof, an effective amount...  
WO/2014/058160A1
According to the present invention, a composition comprising myricetin or a pharmaceutically acceptable salt thereof as an active ingredient enhances exercise performance and physical strength. Also, the composition has an anti-aging fun...  
WO/2014/057178A1
The invention concerns a gaseous composition containing gaseous argon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/057727A1
The purpose is to provide a method for manufacture a fraction containing nobiletin and tangeretin in high concentration and having excellent safety, economic efficiency, and commercialization. The above-stated purpose is achieved by a me...  
WO/2014/059031A2  
WO/2014/059220A1
The invention provides, inter alia, immunoinhibitory glycosphingolipids and immunoinhibitory alpha-galactosylceramides and compositions and preparations thereof, and methods of use thereof including in the treatment of conditions charact...  
WO/2014/056620A1
The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.  
WO/2014/057997A1
The present invention provides: a method for producing a pluripotent spheroid cell, said method comprising introducing a reprogramming peptide containing a nuclear localization signal into a differentiated cell; a preparation for inducin...  
WO/2014/056779A1
The invention relates to a drug for the prophylaxis and/or treatment of a neurodegenerative disease.  
WO/2014/057180A1
The invention concerns a gaseous composition containing a mixture of gaseous xenon and argon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/057484A8
An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X1X2X3X4X5, wherein X1 is a hydrophobic amino acid or threonine, X2 is...  
WO/2014/059363A1
Oral solution formulations of aripiprazole, methods of manufacture of these formulations, methods of administration, and kits containing same.  
WO/2014/058000A1
The purpose of the present invention is to provide a 5-HT2B receptor antagonist which does not induce problematic adverse side effects or the like and can be used safely. Provided are a serotonin 2B receptor antagonist and a prophylactic...  
WO/2014/058875A2
Methods and compositions for enhancing one or more of: myelination, re- myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiment...  
WO/2014/056710A1
The present invention relates to ethynyl derivatives of formula (I) wherein • R is phenyl, 3-fluorophenyl, 4-fluorophenyl or 2,5-di-fluorophenyl; • or to a pharmaceutically acceptable acid addition salt, in enantiomerically pure form...  
WO/2014/056816A1
The present invention relates to a combination of an Aβ antibody and a BACE1 inhibitor.  
WO/2014/057435A1
The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically ac...  
WO/2014/059029A1
Disclosed herein are novel compositions and methods for the treatment of age- related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also d...  
WO/2014/053418A2
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/055588A1
The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 -yl}-phenoxy)-propyl]-diethyl amine ("COMPOUND I") or a pharmaceutically acceptable salt thereof. In various embodim...  
WO/2014/054635A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/055541A1
The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively...  
WO/2014/055977A3
The plasma concentration of at least one branched chain amino acid in a mammal in need of such reduction is reduced by administering an agent that increases the plasma concentration of large neutral amino acids. The invention also includ...  
WO/2014/055932A1
The present invention is an ingestable blended formulation which will cause a series of distinct biochemical changes in-vivo; initiate desirable psychological consequences in that person; and induce an observable increase in cognitive fu...  
WO/2014/055055A1
A pharmaceutical composition for parenteral administration containing the active ingredient 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml for th...  
WO/2014/055949A1
The invention generally features isolated platelets, compositions, methods, and kits useful for targeted delivery of one or more therapeutic agents to a site of injury, inflammation, disease, or disorder. Also featured are methods and ki...  
WO/2014/055047A1
The present invention is related to pharmaceutical compositions comprising idebenone and donepezil for use in symptomatic treatment of cerebral arteriosclerosis, symptoms following stroke and cerebral hemorrhage, age-associated cognitive...  
WO/2014/054965A1
The invention relates to the field of pharmacology and practical medicine, and specifically to the combined use of medicinal preparations, with neuro-tropic action, alleviating the manifestation of mental, behavioural and cognitive di...  
WO/2014/053418A9
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/054634A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/053418A3
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/053857A1
Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. Th...  
WO/2014/054005A3
The invention involves the preparation of cholesterol lecithin nanosomes, without propylene glycol, from the complex formed by quercetin (or another flavonol or flavone or a derivative thereof) and 2-hydroxypropyl-β-cyclodextrin, by mea...  
WO/2014/053580A1
The present invention relates to the anticonvulsant activity of GSK-3βinhibitors and the use of GSK-3β inhibitors as agents for the treatment of neurological disorders characterized by seizures such as epilepsy.  
WO/2014/054651A1
A sleep-improving agent, a non-REM sleep time-increasing agent and a sedative agent, each of which comprises a fat-soluble anti-oxidative substance and a bivalent metal as active ingredients.  
WO/2014/055644A3
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature terminatio...  
WO/2014/055629A1
The present disclosure provides compounds of formula (I): compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased ...  
WO/2014/053409A1
The present invention relates to compounds of general formula wherein R1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or halogen; X1 is N or CH; X2 is N or CH; with the proviso that only one of X1 ...  
WO/2014/055515A1
The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.  
WO/2014/053420A1
The present invention relates to a method for the isolation of mesenchymal stem cells from the blood of mammals, comprising the isolation of mesenchymal stem cells from the blood-interphase of blood samples and preserving said cells in a...  
WO/2014/053210A1
The invention relates to compounds of formula I: wherein R, X and Y, have the meanings given in claim 1. The compounds useful e.g. in the treatment of autoimmune and/or inflammatory disorders, such as multiple sclerosis.  
WO/2014/055916A1
The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.  

Matches 651 - 700 out of 97,147